# Study to Confirm the Efficacy and Safety of Fixed-dose Combinations of Amlodipine and Candesartan

Study · id `cardio:ct-nct03231982` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03231982](<https://clinicaltrials.gov/study/NCT03231982>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03231982

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 210 participants.

## Technical summary

Registry record NCT03231982. Randomized; quadruple masking; primary purpose treatment. Start 2017-04-17 (actual); primary completion 2019-04-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 210 participants (planned count; ClinicalTrials.gov record NCT03231982, source copy `cardio:ctgov-nct03231982-2018-10-16`, retrieved 2026-10-26)
- Started: 2017-04-17 (actual) (ClinicalTrials.gov record NCT03231982, source copy `cardio:ctgov-nct03231982-2018-10-16`, retrieved 2026-10-26)
- Primary completion: 2019-04-30 (anticipated) (ClinicalTrials.gov record NCT03231982, source copy `cardio:ctgov-nct03231982-2018-10-16`, retrieved 2026-10-26)
- Completion: 2019-05-31 (anticipated) (ClinicalTrials.gov record NCT03231982, source copy `cardio:ctgov-nct03231982-2018-10-16`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03231982, source copy `cardio:ctgov-nct03231982-2018-10-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03231982-2018-10-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Confirm the Efficacy and Safety of Fixed-dose Combinations of Amlodipine and Candesartan
- Acronym: MACH
- Condition: Hypertension
- Intervention (Drug): Group I
- Intervention (Drug): Group II
- Lead sponsor: HK inno.N Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: HK inno.N Corporation (`cardio:org-hk-inno-n-corporation`)

## Provenance

Content hash: 26dabed1ce6764c30b538f64fbc460419539ac9fd21b53db19df9bbfbe0bb295
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
